Rybelsus should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (serious metabolic imbalance due to insulin deficiency). Using Rybelsus in combination with a sulfonylurea (oral medicine used to treat type 2 diabetes mellitus) or insulin may increase the risk of low blood sugar (hypoglycemia). To reduce this risk, consider reducing the dose of sulfonylurea or insulin. Cases of acute inflammation of the pancreas (pancreatitis) have been observed when using similar medicines such as Rybelsus (GLP-1 receptor agonists). For this reason, Rybelsus should be used with caution in patients with a history of pancreatitis. Patients must be informed about the typical symptoms of acute pancreatitis. Rybelsus should be discontinued if acute pancreatitis is suspected. The most common undesirable effects associated with taking Rybelsus are stomach and intestinal disorders (nausea, diarrhea, vomiting). These occurred primarily at the beginning of treatment and generally decreased as the duration of treatment progressed. A rapid reduction in blood sugar at the start of treatment may cause a temporary worsening of diabetic retinopathy (a disease of the retina of the eye caused by diabetes mellitus). Long-term improvement in blood sugar control reduces the risk of diabetic retinopathy. Further possible undesirable effects as well as all precautionary measures and risks are listed in the patient information (package insert) and in the specialist information. Extensive studies have shown that the medicine Rybelsus with the active ingredient semaglutide enables effective control of blood sugar as a supplement to adapted diet and exercise. In addition, patients treated with Rybelsus achieved significant weight reduction. These positive effects lasted up to 78 weeks (end of study). Side effects primarily affected the digestive tract (e.g. nausea and vomiting) and diminished with increasing duration of treatment. The available data demonstrate a positive benefit-risk ratio (the benefits outweigh the risks of Rybelsus). Swissmedic has therefore approved the drug Rybelsus with the active ingredient semaglutide for Switzerland. At the time of publication of the Public Summary SwissPAR on Rybelsus, the specialist information and the patient information (package insert) are not yet available. As soon as the medicine is available in Switzerland, the specialist and patient information will be made available on the Internet on the following website: www.swissmedicinfo.ch Questions about the medicine will be answered by medical professionals (doctors, pharmacists and others). .